Browse the evidence

GLP-1 receptor agonists (GLP-1 RAs) are dependent on residual beta-cell function and insulin availability, meaning that as Type 2 Diabetes progresses and beta-cell function declines, GLP-1 RAs lose efficacy and patients eventually require insulin therapy.

If you have Type 2 Diabetes, GLP-1 medications (like Ozempic or Trulicity) work by asking your pancreas to make more insulin. If your pancreas is still working well, these drugs are very effective. However, Type 2 Diabetes is progressive, and your pancreas naturally makes less insulin over time. Eventually, these drugs may stop working well enough on their own. At that point, adding insulin is not a failure; it is the necessary next step to keep your blood sugar safe and protect your body from complications.

GLP-1 agonists (e.g., semaglutide, tirzepatide) significantly delay gastric emptying and increase retained gastric contents, thereby increasing the risk of intraoperative pulmonary aspiration during general anesthesia even after standard preoperative fasting.

If you take GLP-1 agonists (like Ozempic or Wegovy) and are having surgery, tell your anesthesiologist. Standard fasting might not be enough to empty your stomach because these drugs slow digestion. Your doctor may use an ultrasound to check your stomach before surgery or adjust your anesthesia plan to prevent aspiration.

Point-of-care gastric ultrasound is an effective and objective method to assess gastric contents and guide anesthetic management for patients on GLP-1 agonists.

Anesthesiologists should consider using gastric ultrasound to check the stomach contents of patients on GLP-1 agonists before surgery. This helps decide whether to proceed with anesthesia or take extra precautions to prevent aspiration.

Using the Glycemic Index (GI) as a primary indicator for carbohydrate quality fails to improve diet quality or Dietary Guidelines adherence because it ignores nutrient density and food context.

Stop using Glycemic Index (GI) labels or lists to guide your daily food choices. The GI ignores nutrient density and doesn't predict how your body reacts to mixed meals. Instead, focus on the Dietary Guidelines for Americans: eat nutrient-dense foods (vegetables, fruits, whole grains, legumes) in appropriate portions. This approach is more reliable for health than chasing low GI numbers.

Central GIP receptor (GIPR) agonism decreases body weight and food intake in diet-induced obese mice by activating GABAergic neurons in the area postrema, a mechanism that is independent of hypothalamic GIPR signaling.

Newer weight-loss medications that combine GLP-1 and GIP (like tirzepatide) work partly by activating GIP receptors in your brain's satiety centers. This helps reduce food intake. While GIP was once thought to only help with insulin, its role in the brain is now recognized as beneficial for weight loss.

Multi-receptor incretin drugs are associated with an increased risk of adverse events (primarily gastrointestinal) compared to placebo, but do not significantly increase the risk of serious adverse events.

Be aware that multi-receptor incretin drugs commonly cause gastrointestinal side effects like nausea, which may lead to discontinuation for some. However, the risk of serious health events is not significantly higher than placebo. Discuss potential side effects with your doctor and report any severe or persistent symptoms.

Brief lifestyle interventions delivered by generalist community nurses increase client recall of advice and referrals but do not significantly change actual lifestyle behaviors or weight.

If you are a community nurse or healthcare provider, offering brief lifestyle advice is a good start, but it is not enough to change health outcomes on its own. You must actively refer high-risk clients to more intensive, long-term lifestyle programs to see real changes in diet, activity, or weight. Simply giving advice without a pathway to sustained support will not work.

Short-term selective dietary fat restriction (30% calorie reduction) decreases dopamine D2/3 receptor binding potential and neural activity in brain reward regions, leading to increased selection of high-fat, high-carbohydrate foods.

If you are on a low-fat diet, you may find yourself craving high-fat, high-carb foods more intensely. This is likely due to changes in your brain's dopamine system, not just hunger. Be aware that this biological shift can make sticking to a low-fat diet harder, even if you feel satiated by the food itself.

For polygenic obesity, precision medicine approaches targeting specific genetic variants or phenotypes have not yet translated into reliable clinical guidance for selecting obesity medications, making early weight loss response the only consistent predictor of long-term efficacy.

Do not rely on genetic testing or complex phenotyping to choose your obesity medication right now, as it does not reliably predict success for common obesity. Instead, use a 'trial and error' approach guided by side effect profiles, comorbidities, and patient preference. The most important indicator of whether a medication will work for you long-term is whether you lose at least 5% of your body weight within the first 12-16 weeks.

Epicardial adipose tissue (EAT) contributes to Heart Failure with Preserved Ejection Fraction (HFpEF) through two distinct mechanisms: mechanical pericardial restraint and local inflammatory/fibrotic secretion.

For patients with HFpEF, managing epicardial fat is crucial. While general weight loss helps, specific interventions like bariatric surgery or Mediterranean-style diets have been shown to reduce EAT volume and improve heart mechanics. Monitoring EAT via imaging can help assess risk and treatment efficacy.

Bariatric surgery is the most effective intervention for reducing epicardial fat volume and improving HFpEF outcomes, superior to modest lifestyle changes.

For obese HFpEF patients, bariatric surgery is the most effective way to reduce epicardial fat and improve heart function. It reduces EAT more effectively than modest lifestyle changes. Consult with a bariatric specialist to see if you are a candidate.

Visceral fat accumulation activates the Renin-Angiotensin-Aldosterone System (RAAS) and Sympathetic Nervous System (SNS), leading to hypertension and sodium retention, independent of dietary salt intake.

High blood pressure in obesity is driven by hormones from belly fat, not just salt. Reducing visceral fat helps normalize these hormones and lower blood pressure.

Obesity increases the risk of various cancers, including breast, endometrial, ovarian, kidney, thyroid, and gastrointestinal cancers, through mechanisms involving chronic inflammation, adipokine secretion, and epigenetic dysregulation.

Obesity increases your risk of several types of cancer, including breast, endometrial, and gastrointestinal cancers. This risk is driven by chronic inflammation and hormones secreted by fat tissue.

A 12-week self-guided resistance training program does not significantly improve muscle strength or muscle mass in women with generalized joint hypermobility (GJH).

If you have generalized joint hypermobility, simply doing resistance exercises twice a week on your own is unlikely to build strength or muscle. You likely need higher intensity (heavier loads) and direct supervision to ensure proper progression and safety.

In patients with type 2 diabetes and recent acute coronary syndrome, a body weight loss of 5% or more is independently associated with a significantly higher risk of all-cause mortality and cardiovascular events.

If you have diabetes and a history of heart issues, losing more than 5% of your body weight without trying is a medical emergency. It often signals worsening heart failure, kidney disease, or other serious conditions. Do not view this weight loss as a success; consult your doctor immediately to investigate the cause.

In patients with type 2 diabetes and recent acute coronary syndrome, a higher baseline Body Mass Index (BMI > 30 kg/m2) is associated with a lower risk of primary cardiovascular outcomes compared to those with a BMI of 26-30 kg/m2.

If you have diabetes and recent heart issues, having a higher BMI (over 30) might actually protect you from cardiovascular events compared to being 'normal' weight. Do not attempt aggressive weight loss unless advised by your doctor, as maintaining your current weight may be beneficial for your heart.

Acute exercise (both HIIT and MICT) results in more phosphosite down-regulation than up-regulation, suggesting that acute exercise involves the inhibition of kinase activity and/or activation of phosphatases.

Exercise doesn't just turn things on; it also turns things off. This balance is crucial for adaptation. Don't assume more activation is always better; regulation (inhibition) is part of the process.

Roux-en-Y Gastric Bypass (RYGB) and Laparoscopic Sleeve Gastrectomy (LSG) induce significantly greater cardiac reverse remodelling (reduction in left ventricular mass and concentric remodelling) than Laparoscopic Adjustable Gastric Band (LAGB) in obese patients.

If you are considering bariatric surgery for obesity, the type of surgery matters for your heart health. Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (LSG) are superior to Gastric Banding (LAGB) in reversing the structural changes in the heart caused by obesity. This benefit is driven by the greater reduction in visceral and epicardial fat, not just total weight loss. Discuss cardiac imaging and long-term heart health with your surgeon when choosing between these procedures.

Standard RNA-seq normalization strategies that ignore global changes in total RNA content during resistance training produce counterintuitive, biologically invalid results by failing to account for increased ribosomal biogenesis and tissue mass.

If you are analyzing muscle gene expression after resistance training, do not use standard normalization methods that assume total RNA remains constant. You must account for the increase in total RNA (ribosomal biogenesis) caused by muscle growth, or your results will be biologically invalid and counterintuitive.

Higher visceral adipose tissue (VAT) is independently associated with greater impairment in left ventricular peak circumferential strain (Ecc), indicating reduced myocardial contractility, regardless of cardiorespiratory fitness (CRF) or other regional fat depots.

Focus on reducing visceral fat (belly fat) rather than just total body weight. Even if you are not obese, high visceral fat is linked to early heart muscle dysfunction. Cardiovascular exercise and weight management are key to reducing this specific fat depot.

Endogenous gut-derived GLP-1, secreted in response to nutrients or non-caloric stimuli (like gastrointestinal distension), regulates feeding behavior and glucose metabolism via vagal sensory nerves without causing the adverse effects (nausea/vomiting) associated with GLP-1 receptor agonists.

You can influence your GLP-1 levels naturally. Eating GLP-1-stimulating foods (meat, fish, salad) first, followed by a wait before carbs, improves glycemic control and weight loss. Gastrointestinal distension from bulky, low-energy-density foods also triggers beneficial GLP-1 secretion via vagal nerves without causing nausea.

Weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces liver steatosis and liver enzymes in patients with NAFLD/NASH, but does not significantly improve liver fibrosis or achieve NASH resolution compared to placebo in patients with compensated cirrhosis.

For patients with advanced liver disease (cirrhosis), weekly semaglutide injections (2.4 mg) can significantly reduce liver fat and inflammation markers, but they should not expect it to reverse scarring (fibrosis) or cure NASH. The treatment is safe and effective for metabolic control and steatosis reduction, even if it doesn't change the fibrosis stage.

Intentional weight loss in individuals with Type 2 Diabetes (T2D) is not consistently associated with reduced mortality risk and may be associated with higher mortality in obese subgroups, whereas weight cycling (body weight variability) is consistently associated with significantly increased all-cause and cardiovascular disease mortality.

If you have Type 2 Diabetes, do not focus on weight loss as a primary goal for reducing mortality risk. Instead, prioritize increasing physical activity and improving cardiorespiratory fitness. Weight cycling (losing and regaining weight) is associated with higher mortality risk, so maintaining a stable weight while improving fitness is a safer and more effective strategy for longevity.

There is no statistically significant association between the intake of total fat, saturated fatty acids (SFA), or polyunsaturated fatty acids (PUFA) and the incidence of cardiovascular disease.

You do not need to fear total fat or saturated fat intake in isolation. This study found that the amount of total fat or saturated fat consumed did not significantly predict cardiovascular disease risk. Instead, focus on the specific types of fats you consume, particularly increasing monounsaturated and omega-3 fats.